"Umoja Biopharma, Inc. is a pre-clinical stage biotechnology company located in Seattle WA. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja is advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo."
"Umoja's novel approach is powered by an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies."
"Designed from the ground up to work together, these platforms create and harness a powerful immune response in the body to directly, safely and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives."
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze